Allan Reine
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
-
Current
-
Current
-
Current
-
Start not stated–2024-01-16
Company network
Recorded roles and earnings-call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Prime Medicine, Inc. (PRME) | Chief Executive Officer | $606,212 | $3,894,187 |
| 2024 | Prime Medicine, Inc. (PRME) | Chief Financial Officer | $479,489 | $4,623,802 |
| 2023 | Prime Medicine, Inc. (PRME) | Chief Financial Officer | — | — |
| 2022 | Foghorn Therapeutics Inc. (FHTX) | Chief Financial Officer | $435,000 | $1,987,269 |
| 2021 | Foghorn Therapeutics Inc. (FHTX) | Chief Financial Officer | $416,000 | $2,014,346 |
Recent activity
No earnings-call appearances or filed executive changes recorded yet.